GlobeNewswire

LifeSci Advisors Announces 10th Board Appointment Through Board Placement Initiative

Dela

Dr. Kristine Swiderek Appointed to the Board of Directors of Sitka Biopharma Inc.

NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) --  LifeSci Advisors, an investor relations and corporate communications firm focused on the life sciences sector, announced today the 10th placement of a female executive to a life sciences company board as part of its Board Placement Initiative (BPI). LifeSci Advisors launched BPI last year with the goal of connecting female executives in the life sciences industry with companies looking for board candidates. The company is pleased to share that Dr. Kristine Swiderek, Co-founder and Chief Scientific Officer of OncoResponse, has joined the Board of Directors of Sitka Biopharma Inc., a Canadian biotechnology company focused on developing its breakthrough nanoparticle platform technology to increase absorption of drugs in difficult-to-penetrate tissues. Dr. Swiderek's placement marks a milestone for BPI as the 10th successful appointment made by the program in just one year. LifeSci Advisors will continue to make connections and look to match more candidates in the coming months.

"I am honored to serve on the Board of Directors of Sitka Biopharma," said Dr. Swiderek. "I look forward to helping the company as it works to advance products in the industry and improve the lives of patients. I would like to thank LifeSci Advisors for facilitating this introduction and the work the Board Placement Initiative is doing to place talented, qualified women on the boards of companies in the life sciences industry."

Dr. Swiderek is the Co-founder and Chief Scientific Officer of venture backed OncoResponse, a company focusing in immuno-oncology, discovering and developing novel cancer Immunotherapies. She brings deep expertise in clinical, R&D, partnering and alliance management to Sitka's Board. Previously as CSO at Theraclone Sciences, she formed multiple R&D partnerships with Pfizer, Gilead, non-profit organizations and academia and helped advance therapeutic candidates into the clinic. She also served as Vice President, Protein Science at ZymoGenetics, a public company, where she managed extensive internal and external partner portfolios. As Senior Director in Protein Biochemistry, she helped develop the PEG-Interferon lambda program, which ultimately was a cornerstone for a $1.1B partnership with Bristol-Myers Squibb. Dr. Swiderek did her post-doctoral training at the City of Hope, CA, and Indiana University following a Ph.D. at Ruhr-Universität Bochum, Germany. Dr. Swiderek is currently based in Seattle, WA.

"Dr. Swiderek's experience will be an incredible asset to the Sitka Board of Directors," said Michael Rice, President and Co-Founder, LifeSci Advisors. "We are thrilled that LifeSci Advisors' Board Placement Initiative has been able to play a role in facilitating this appointment and excited to mark this milestone of our 10th board placement in just one year. Our program is designed to support women in our industry and make the life sciences a more diverse and inclusive space. We look forward to continuing to successfully match candidates with companies across the industry and hope to see more placements in the coming months."

"We are pleased to welcome Dr. Swiderek to the Sitka Biopharma Board," said Dr. Michael Parr, President and Chief Scientific Officer, Sitka Biopharma. "Her energy and expertise in clinical development will prove invaluable as we continue to advance our leading product toward the clinic, and ultimately improve the lives of patients living with bladder cancer. I'd like to thank LifeSci Advisors for making an introduction to such a great board director." 

LifeSci Advisors' Board Placement Initiative (BPI) was launched in the summer of 2016 with the goal of helping companies in the life sciences industry diversify and strengthen their company boards. Connections between companies and eligible board candidates are made after LifeSci has met with a company's management team or board regarding the skills and expertise they are looking for in a candidate, and after the LifeSci team has properly vetted the board candidates. BPI has now helped to place ten women on corporate boards, and is looking to continue to expand upon this success. With a proprietary online network of hundreds of resumes of board-ready women, LifeSci Advisors hopes that BPI can become a resource for both women executives and life sciences companies to network and grow.

BPI is accepting resumes from interested candidates and referrals on an ongoing basis. To find out how you can use the BPI network for your next board candidate search, visit www.lifesciadvisors.com/board-diversity-initiatives. Inquiries, resume submissions, and open board seat referrals can be sent to boarddiversity@lifesciadvisors.com.

LifeSci Advisors, LLC (www.lifesciadvisors.com) is a unique investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. With a local presence in New York, Boston, Chicago, Philadelphia, London, Geneva and Tel Aviv, the firm provides the highest quality service for its clients through its deep sector specialization. Our roster of PhDs enables us to better understand our clients' R&D, regulatory, and commercial strategies, and our team of financial services, investor relations, and public relations specialists help our clients effectively communicate to the marketplace. This combination of life sciences, financial services, and investor relations competencies allows us to provide a valuable and unique service offering to our clients.

LifeSci Partners (www.lifescipartners.com) is the leading provider of comprehensive consulting services in the areas of investor relations, corporate communications, public relations and capital markets advisory.  Combining deep domain expertise in the life sciences with decades of experience in capital markets and public relations, we deliver unparalleled services to life sciences companies globally.  LifeSci Partners has a physical presence in New York, Boston, Chicago, Philadelphia, London, Geneva and Tel Aviv.

For further information, please contact:

Ann Kaiser                                                                                          
The TASC Group
212-337-8870
ann@thetascgroup.com

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LifeSci Advisors, LLC via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement15.10.2018 13:25Pressmeddelande

STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health. Palette Life Sciences (former Pharmanest) has announced a licensing agreement with Nestlé Skin Health. The agreement gives Palette Life Sciences the worldwide commercialization and development rights for three products: Deflux®, Solesta® and BarrigelTM. The products are all based on the NASHATM (Non Animal Stabilized Hyaluronic Acid) technology. Palette Life Sciences will focus immediately on sales of Deflux and Solesta and will begin preparing for worldwide commercialization of Barrigel. Nestlé Skin Health will continue to manufacture the products on behalf of Palette Life Sciences. Palette Life Science will continue the development of SHACT under the name LidbreeTM. Lidbree will be submitted for European regulatory review later this year. Karolinska Development is a passive investo

Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement15.10.2018 13:25Pressmeddelande

STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health. Palette Life Sciences (former Pharmanest) has announced a licensing agreement with Nestlé Skin Health. The agreement gives Palette Life Sciences the worldwide commercialization and development rights for three products: Deflux®, Solesta® and BarrigelTM. The products are all based on the NASHATM (Non Animal Stabilized Hyaluronic Acid) technology. Palette Life Sciences will focus immediately on sales of Deflux and Solesta and will begin preparing for worldwide commercialization of Barrigel. Nestlé Skin Health will continue to manufacture the products on behalf of Palette Life Sciences. Palette Life Science will continue the development of SHACT under the name LidbreeTM. Lidbree will be submitted for European regulatory review later this year. Karolinska Development is a passive investo

ICONOVO TECKNAR AVTAL MED MCMASTER UNIVERSITY AVSEENDE UTVECKLING AV VACCIN MOT TUBERKULOS15.10.2018 09:00Pressmeddelande

Det innovativa, Lundabaserade medicinteknikföretaget Iconovo AB (publ) meddelar i dag att bolaget har skrivit samarbetsavtal med McMaster University i Kanada. Avtalet avser utveckling av en torrpulverberedning av inhalerbart vaccin mot tuberkulos som ska användas i Iconovos unika engångsinhalator ICOone. Iconovo kommer att ingå i ett tvärvetenskapligt forsknings- och utvecklingsprojekt som syftar till att ta fram nästa generations virusbaserade vaccin i pulverform som är stabilt i rumstemperatur. Att kunna transportera vaccin utan krav på kylförvaring är en förutsättning för att snabbt och effektivt nå ut till de behövande. I det projekt som nu påbörjas kommer Iconovos unika engångsinhalator ICOone att användas som testplattform för att underlätta en framtida kommersialisering och storskalig tillverkning. Projektet beräknas pågå i tre år och finansieras bland annat av den kanadensiska staten (CIHR/NSERC). Tuberkulos förekommer i hela världen och är en av de tio vanligaste dödsorsakerna

Stillfront Group AB: Babil Games lanserar Arab Gamers' League4.10.2018 10:02Pressmeddelande

PRESSMEDDELANDE 4 oktober 2018 Babil Games, en del av Stillfront Group, ökar affärstillväxten och lanserar Arab Gamers' League, AGL Babil Games, ett dotterbolag till Stillfront Group, inleder partnerskap med kreativa byrån Grape Creations i Dubai och lanserar Arab Gamers' League (AGL), en ny studio som fokuserar på att lansera så kallade 'social casual games' till MENA-regionen. Babil Games kontrollerar 51% av AGL och Grape Creations övriga 49%. Babil Games är ansvarig för verksamheten och sourcing av spel medan Grape Creations ansvarar för marknadsföring och distribution. "Vi är mycket glada över vårt inledda partnerskap med Grape Creations gällande lanseringen av Arab Gamers' League. AGLs fokus är att lansera nästa generations 'social casual games' till MENA-regionen", säger MJ Fahmi, VD för Babil Games. Babil Games kommer att fortsätta att fokusera på MMO-strategispel. Antalet anställda i Babil Games har fördubblats under det senaste året och studion kommer att flytta till ett nytt

Stillfront Group AB: Babil Games launches Arab Gamers' League4.10.2018 10:02Pressmeddelande

PRESS RELEASE 4 October 2018 Babil Games, part of the Stillfront Group, accelerates business growth and launches Arab Gamers' League, AGL Babil Games, a subsidiary of Stillfront Group, is partnering with Dubai based creative agency Grape Creations to launch Arab Gamers' League (AGL), a new studio focused on bringing social casual games to the MENA-region. Babil Games controls 51% of AGL and Grape Creations the other 49%. Babil Games is head of the operations and the sourcing of the games while Grape Creations is responsible for marketing and distribution. "We are pleased to have Grape Creations as our partner for the launch of Arab Gamers League. In AGL we will focus on bringing the next generation of social casual games to the MENA region", says MJ Fahmi, CEO of Babil Games. Babil Games will continue to focus on strategy MMO games. The number of employees in Babil Games has doubled during the year and the studio will relocate to a new larger office in Amman, Jordan. "The expansion is

Hoylu AB: UNITED STATES AIR FORCE SELECTS HOYLU FOR COLLABORATION AND INNOVATION SOLUTIONS28.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 28, 2018 - Hoylu, a leading enterprise collaboration company announced today that the United States Air Force has selected Hoylu Software and multiple large format HoyluWall systems as a digital workspace tool for workspace innovation and collaboration. Hoylu software will be used at multiple sites to create joined environments within the division. The order will be delivered in Q4 2018 and represents a deal value of SEK 3,670,000 in product and software revenue. The Air Force will use the system for training and education purposes, with the ability to connect users together and collaborate in real-time. The order represents a growing market for Hoylu software and services within the government sector. It is expected that Hoylu's solutions will continue to expand within this industry as innovative collaboration solutions are in demand. Hoylu's solutions and software offer new and exciting ways to learn and collaborate smarter, faster and more efficiently. Creat

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum